Keytruda in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival, compared with standard of care chemotherapy.
Researchers at the Keck School of Medicine have identified a variant in the genome that may explain why multiple men in the same family develop the disease—and could serve as a guide for screening,
New research from Mass General Cancer Center, published in JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living like walking, bathing, getting dressed, or other routine tasks.
Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses.
Yale Cancer Center scientists have developed a cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called “traptamers” and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19.
In the midst of the heavy burden COVID-19 has placed on the health care system, cancer remains relentless. The already difficult journey for cancer patients has become more uncertain as the ways we provide and access healthcare have changed to accommodate measures that protect both health care providers and cancer patients from COVID-19.
EGFR Resisters and LUNGevity Foundation have issued a Request for Application for the EGFR-Positive lung cancer research program.
The FY20 Defense Appropriations Act provides funding to the Department of Defense Pancreatic Cancer Research Program to support pancreatic cancer research.
The American Cancer Society is reducing its overall budget by approximately 30%, with cuts to non-personnel and personnel expenses as a result of a decrease in fundraising revenue.
ASCO's CancerLinQ launched the SmartLinQ QOPI Certification Pathway, an application that allows oncology practices to automate quality measure tracking and reporting for participation in ASCO's Quality Oncology Practice Initiative Certification Program, a three-year certification recognizing practices' commitment to high-quality care for outpatient oncology practices.
